Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: Impact of rituximab on immunomodulation and survival

Experimental Hematology

Volumn 32, Issue 1, 2004, Pages 28-35

  Khouri, Issa F ^a   Lee, Ming Sheng ^a   Saliba, Rima M ^a   Andersson, Borje ^a   Anderlini, Paolo ^a   Couriel, Daniel ^a   Hosing, Chitra ^a   Giralt, Sergio ^a   Korbling, Martin ^a   McMannis, John ^a   Keating, Michael J ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTYPE SUPPRESSION; ARTICLE; BLOOD DONOR; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; LYMPHOCYTE TRANSFUSION; MALE; PRIORITY JOURNAL; REFRACTORY PERIOD; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 9144253902     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2003.09.021     Document Type: Article

References (27)

1. Keating M.J. Chronic lymphocytic leukemia. Semin Oncol. 26:(suppl 14):1999;107-114.
2. Keating M., O'Brien S., Lerner S., et al. Combination chemo-antibody therapy with fludarabine, cyclophosphamide, and rituximab achieves high CR rate in previously untreated chronic lymphocytic leukemia. Blood. 96:2000;514a.
3. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-IH) in patients who have failed fludarabine: results of a large international study. Blood. 99:2000;3554-3561.
4. Khouri I.F., Przepiorka D., van Besien K., et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia: timing of transplantation and potential effect of fludarabine on acute graft-vs-host disease. Br J Haematol. 97:1997;466-473.
5. Khouri I.F., Keating M.J., Saliba R., Champlin R.E. Long term follow-up of patients with chronic lymphocytic leukemia treated with allogeneic hematopoietic transplantation. Cytotherapy. 4:2002;217-221.
6. Khouri I.F., Keating M.J., Champlin R.E. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Hematol. 5:1998;454-459.
7. Bredeson C.N., Sobocinski K.A., Giralt S., et al. Salvage therapy for CLL: HLA-identical sibling transplantation vs non-transplant therapies: an international bone marrow transplant registry and M.D. Anderson Cancer Center (MDACC) study. Blood. 98:2001;482a.
8. Rondon G., Giralt S., Huh Y., et al. Graft-vs-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 18:1996;669-672.
9. Esteve J., Villamor N., Colomer D., Cervantes F., Carreras E., Montserrat E. Stem cell transplantation for chronic lymphocytic leukemia: Different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia. 15:2001;445-451.
10. Khouri I.F., Keating M.K., Korbling M., et al. Transplant-lite: Induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment of lymphoid malignancies. J Clin Oncol. 16:1998;2817-2824.
11. Khouri I.F., Saliba R., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-vs-host disease, and treatment-related mortality. Blood. 98:2001;3595-3599.
12. O'Brien S.M., Kantarjian H., Thomas D., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 19:2001;2165-2170.
13. Przepiorka D., Weisdorf D., Martin P., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 15:1995;825-828.
14. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-Sponsored Working Guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 87:1996;4990-4997.
15. Khouri I.F., Lee M.S., Romaguera J., et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remission and evidence of graft-vs-malignancy. Ann Oncol. 10:1999;1293-1299.
16. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
17. Kalbfleish J.D., Prentice R.L. The statistical analysis of failure time data. 1980;John Wiley, New York.
18. Klein J.P., Keiding N., Shu Y., Szydlo R.M., Goldman J.M. Summary curves for patients transplanted for chronic myeloid leukemia salvaged by a donor lymphocyte infusion: the current leukemia-free survival curve. Br J Haematol. 109:2000;148-152.
19. Cox D.R. Regression models and life-tables (with discussion). J R Stat Soc. B34:1972;187-220.
20. Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1:1945;80-83.
21. Michallet M., Archimbaud E., Bandini G., et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med. 24:1996;311-315.
22. Rabinowe S.N., Soiffer R.J., Gribben J.G., et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 82:1993;1366-1376.
23. Pavletic Z.S., Arrowsmith E.R., Bierman P.J., et al. Outcome of allogeneic stem cell transplantation for B chronic lymphocytic leukemia. Bone Marrow Transplant. 25:2000;717-722.
24. Horowitz M.M., Montserrat E., Sobocinski K., Giralt S., Khouri I.F., Schmitz N. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Blood. 96:2000;522a.
25. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 6:2000;443-446.
26. Hsu F.J., Komarovskaya M. CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother. 25:2002;455-468.
27. Schultz K.R., Paquet J., Bader S., HayGlass K.T. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-vs-host disease. Bone Marrow Transplant. 16:1995;289-295.